MDL 204
Alternative Names: MDL-204Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Modalis Therapeutics
- Developer Astellas Pharma; Modalis Therapeutics
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in CNS-disorders in Japan (Parenteral)
- 28 Aug 2020 Preclinical trials in CNS disorders in Japan (Parenteral) before August 2020
- 01 Apr 2020 Modalis Therapeutics in-licenses CRISPR gene editing technology from Editas Medicine